Tumor Biology

, Volume 37, Issue 11, pp 14999–15005 | Cite as

Gamma-synuclein binds to AKT and promotes cancer cell survival and proliferation

  • Zengxia Ma
  • Jianyi Niu
  • Erlian Sun
  • Xuedong Rong
  • Xianxin Zhang
  • Yuanrong Ju
Original Article


Hyperactivation of AKT plays a critical role in the survival and proliferation of cancer cells. However, the molecular mechanisms underlying AKT activation remain elusive. Here, we tested the effect of γ-synuclein, a member of the synuclein family of proteins, on the activation of AKT. We show that the expression level of γ-synuclein is increased in non-small cell lung cancer (NSCLC) tissues. γ-Synuclein binds to the protein kinase domain of AKT and promotes its phosphorylation. Overexpression of γ-synuclein in H157 cells enhances cell proliferation and protects the cells from staurosporine-induced cytotoxicity. Knockdown of γ-synuclein attenuates AKT activation and cell proliferation induced by epidermal growth factor. The effect of γ-synuclein is abolished when AKT is depleted. Thus, γ-synuclein promotes cell survival and proliferation via activating AKT and may play a causal role in the pathogenesis of NSCLC.


γ-Synuclein Non-small cell lung cancer H157 cells AKT 


  1. 1.
    Esposito L, Conti D, Ailavajhala R, Khalil N, Giordano A. Lung cancer: are we up to the challenge? Curr genomics. 2010;11(7):513–8.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75(1 Suppl):191–202.CrossRefPubMedGoogle Scholar
  3. 3.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–500.CrossRefPubMedGoogle Scholar
  6. 6.
    Lemjabbar-Alaoui H, Hassan OU, Yang Y-W, Buchanan P. Lung cancer: biology and treatment options. Biochim Biophys Acta. 2015;1856(2):189–210.PubMedGoogle Scholar
  7. 7.
    Zhu G, Fan Z, Ding M, Zhang H, Mu L, Ding Y, et al. An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven tumorigenesis. Oncogene. 2015;34(49):5971–82.CrossRefPubMedGoogle Scholar
  8. 8.
    Lastwika KJ, Wilson W, Li QK, Norris J, Xu H, Ghazarian SR, et al. Control of PD-L1 expression by oncogenic activation of the AKT–mTOR pathway in non–small cell lung cancer. Cancer Res. 2016;76(2):227–38.CrossRefPubMedGoogle Scholar
  9. 9.
    Settleman J, Kurie JM. Drugging the bad “AKT-TOR” to overcome TKI-resistant lung cancer. Cancer Cell. 2007;12(1):6–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Zhou H, Huang S. Role of mTOR signaling in tumor cell motility, invasion and metastasis. Curr Protein Peptide Sci. 2011;12(1):30.CrossRefGoogle Scholar
  11. 11.
    Franke T. PI3K/Akt: getting it right matters. Oncogene. 2008;27(50):6473–88.CrossRefPubMedGoogle Scholar
  12. 12.
    Guo G, Gong K, Wohlfeld B, Hatanpaa KJ, Zhao D, Habib AA. Ligand-independent EGFR signaling. Cancer Res. 2015;75(17):3436–41.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hill MM, Hemmings BA. Hemmings, inhibition of protein kinase B/Akt: implications for cancer therapy. Pharmacol Ther. 2002;93(2):243–51.CrossRefPubMedGoogle Scholar
  14. 14.
    Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, et al. Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004;25(11):2053–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int. 2007;57(10):664–71.CrossRefPubMedGoogle Scholar
  16. 16.
    Spoerke JM, O’Brien C, Huw L, Koeppen H, Fridly J, Brachmann RK, et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res. 2012;18(24):6771–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Singh VK, Jia Z. Targeting synuclein-γ to counteract drug resistance in cancer. Expert Opin Ther Targets. 2008;12(1):59–68.CrossRefPubMedGoogle Scholar
  18. 18.
    Duyckaerts C. Neurodegenerative lesions: seeding and spreading. Rev Neurol. 2013;169(10):825–33.CrossRefPubMedGoogle Scholar
  19. 19.
    Lavedan C, Leroy E, Dehejia A, Buchholtz S, Dutra A, Nussbaum RL, et al. Identification, localization and characterization of the human γ-synuclein gene. Hum Genet. 1998;103(1):106–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Liu J, Spence MJ, Zhang YL, Jiang Y, Liu YE, Shi YE. Transcriptional suppression of synuclein γ (SNCG) expression in human breast cancer cells by the growth inhibitory cytokine oncostatin M. Breast Cancer Res Treatment. 2000;62(2):99–107.CrossRefGoogle Scholar
  21. 21.
    Ahmad M, Attoub S, Singh MN, Martin FL, El-Agnaf OM. γ-synuclein and the progression of cancer. FASEB J. 2007;21(13):3419–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Liu H, Liu W, Wu Y, Zhou Y, Xue R, Luo C, et al. Loss of epigenetic control of synuclein-γ gene as a molecular indicator of metastasis in a wide range of human cancers. Cancer Res. 2005;65(17):7635–43.PubMedGoogle Scholar
  23. 23.
    Jiang Y, Liu YE, Lu A, Gupta A, Goldberg ID, Liu J, et al. Stimulation of estrogen receptor signaling by γ synuclein. Cancer Res. 2003;63(14):3899–903.PubMedGoogle Scholar
  24. 24.
    Jia T, Liu YE, Liu J, Shi YE. Stimulation of breast cancer invasion and metastasis by synuclein γ. Cancer Res. 1999;59(3):742–7.PubMedGoogle Scholar
  25. 25.
    Gupta A, Inaba S, Wong OK, Fang G, Liu J. Breast cancer-specific gene 1 interacts with the mitotic checkpoint kinase BubR1. Oncogene. 2003;22(48):7593–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Du K, Tsichlis PN. Regulation of the Akt kinase by interacting proteins. Oncogene. 2005;24(50):7401–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Hashimoto M, Bar-On P, Ho G, Takenouchi T, Rockenstein E, Crews L, et al. Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson’s disease. J Biol Chem. 2004;279(22):23622–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001;61(10):3986–97.PubMedGoogle Scholar
  29. 29.
    Toulany M, Rodemann HP. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation. Semin Cancer Biol. 2015;35:180–90.CrossRefPubMedGoogle Scholar
  30. 30.
    Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.CrossRefPubMedGoogle Scholar
  31. 31.
    Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S, et al. Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung. Cell Cycle. 2008;7(5):665–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448(7152):439–44.CrossRefPubMedGoogle Scholar
  33. 33.
    Beck JT, Ismail A, Tolomeo C. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev. 2014;40(8):980–9.CrossRefPubMedGoogle Scholar
  34. 34.
    Gadgeel SM, Wozniak A. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non–small-cell lung cancer. Clin Lung Cancer. 2013;14(4):322–32.CrossRefPubMedGoogle Scholar
  35. 35.
    Meng J, Dai B, Fang B, Bekele BN, Bornmann WG, Sun D, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010;5(11):e14124.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Ji H, Liu YE, Jia T, Wang M, Liu J, Xiao G, et al. Identification of a breast cancer-specific gene, BCSG1, by direct differential cDNA sequencing. Cancer Res. 1997;57(4):759–64.PubMedGoogle Scholar
  37. 37.
    Buchman VL, Hunter HJ, Pinõn LG, Thompson J, Privalova EM, Ninkina NN, et al. Persyn, a member of the synuclein family, has a distinct pattern of expression in the developing nervous system. J Neurosci. 1998;18(22):9335–41.PubMedGoogle Scholar
  38. 38.
    Wu K, Quan Z, Weng Z, Li F, Zhang Y, Yao X, et al. Expression of neuronal protein synuclein γ gene as a novel marker for breast cancer prognosis. Breast Cancer Res Treatment. 2007;101(3):259–67.CrossRefGoogle Scholar
  39. 39.
    Liang W, Miao S, Zhang B, He S, Shou C, Manivel P, et al. Synuclein γ protects Akt and mTOR and renders tumor resistance to Hsp90 disruption. Oncogene. 2015;34(18):2398–405.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Zengxia Ma
    • 1
    • 2
  • Jianyi Niu
    • 3
  • Erlian Sun
    • 1
  • Xuedong Rong
    • 2
  • Xianxin Zhang
    • 2
  • Yuanrong Ju
    • 1
  1. 1.Department of RespiratoryShandong Provincial Hospital Affiliated to Shandong UniversityJinanChina
  2. 2.Department of RespiratoryShandong Provincial Chest HospitalJinanChina
  3. 3.Department of Neurology, Yidu Central HospitalWeifang Medical UniversityQingzhouChina

Personalised recommendations